Grifols acquires Pharmalink's treatment for post-polio syndrome
This article was originally published in Scrip
Grifols of Spain has acquired Xepol, an investigational treatment programme for post-polio syndrome (PPS) based on a human immunoglobulin, from the Swedish company Pharmalink. Financial details have not been disclosed, but the companies said there would be up-front and milestone payments.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.